Papers, awards, clinic numbers

Research and Scientific Evidence

We treat from blood biomarkers, not from a scan report alone. Below is the published work, the awards, and outcome data from 100,000+ patients. Read it like a clinician: what was measured, in whom, and what changed.

120+

Published Studies

Peer-reviewed papers in indexed journals

100,000+

Patients Treated

Total patients treated across OPTM clinics

89%

Knee Surgery Avoidance

Documented Grade 1-3 knee cohort, 2019-2024

60+

Biomarkers Analyzed

Blood markers the scan report never lists

Published Clinical Studies

Peer-reviewed, NIH-indexed journals. Same protocol we run in Delhi, Kolkata, and Panchkula.

AI-Powered Biomarker Analysis for Chronic Pain Diagnosis

PubMed Central (NIH)2025

This publication examined molecular signatures associated with varicosity across ten biomarker panels and shows how multi-marker data can be organized for diagnostic research.

Key Findings:

  • Uses multiple biomarker panels rather than one isolated marker
  • Reports a molecular-signature approach to diagnostic research
  • Provides a directly inspectable source for technical readers

Pain Diagnostic Protocol and Topical Phytotherapeutic Treatment for Osteoarthritic Disorders

International Online Medical Council Proceedings2023

This paper describes a pain-diagnostic and topical phytotherapeutic protocol for osteoarthritic disorders. It should be read as protocol-level clinical research, not as proof that every person with osteoarthritis can avoid surgery.

Key Findings:

  • Connects diagnostic assessment with a topical phytotherapeutic approach
  • Focuses on osteoarthritis care rather than general pain claims
  • Provides the full publication record for independent review

Efficacy of Phytotherapeutic Protocol for Risk-Factor Reduction in Musculoskeletal Degeneration

International Archives of BioMedical and Clinical Research2024

This systematic meta-analysis evaluates a phytotherapeutic protocol in relation to musculoskeletal-degeneration risk factors. Readers should review the included studies, definitions, and limitations before drawing conclusions.

Key Findings:

  • Systematically reviews protocol-level evidence
  • Addresses musculoskeletal-degeneration risk factors
  • Makes the underlying publication available for source review

How to read the clinic evidence

A responsible outcome statement names the population, the time window, the measurement, and the limits. We use those details instead of presenting one percentage for every diagnosis.

The documented knee-replacement avoidance cohort

In a documented cohort of more than 1,000 patients with Grade 1-3 knee osteoarthritis observed from 2019 to 2024, 89% avoided a knee-replacement recommendation after receiving the OPTM protocol. The figure is specific to that cohort and follow-up window. It is not a claim that 89% of all patients avoid surgery, and it does not replace imaging, specialist review, or a decision about advanced disease.

1,000+

Patients in the documented knee cohort

Grade 1-3

Disease range included in the cohort

89%

Avoided a knee-replacement recommendation

Knee Osteoarthritis

Patients Studied1,000+ documented Grade 1-3 knee patients
Avg. Pain ReductionCohort-specific; not generalized across all grades

All other conditions

Patients StudiedOutcomes tracked clinically
Avg. Pain ReductionReviewed case by case during follow-up

Advanced or Grade 4 disease

Patients StudiedRequires specialist evaluation
Avg. Pain ReductionSafety and staged care take priority

Cause outside the protocol

Patients StudiedReferred when indicated
Avg. Pain ReductionCoordinated with the relevant medical specialty

What our publications do—and do not—establish

The evidence on this page supports specific parts of the OPTM approach: biomarker-oriented assessment, structured pain protocols, topical phytotherapeutic research, and risk-factor reduction in musculoskeletal degeneration. These publications should not be read as a guarantee of pain relief, cartilage regeneration, or avoidance of surgery for every patient.

For a person considering care, the practical questions are different from a marketing statistic: Which diagnosis is being treated? What grade or stage is it? Which biomarkers or clinical findings changed the plan? Is surgery or another specialty referral necessary now? How will progress be reviewed, and what happens if the response is inadequate?

OPTM's role is to document the baseline, apply a staged protocol where appropriate, measure change during follow-up, and escalate when the clinical picture requires it. Grade 4 disease, progressive neurological symptoms, infection, fracture, or another urgent finding may require a surgical or specialist pathway before non-surgical care is offered.

Direct source links

Each item below opens the cited publication or an author index. These links let patients and professionals verify the title, venue, year, method, and stated limitations.

Research and evidence questions

Is OPTM's treatment clinically proven?

Evidence is component-specific rather than a blanket guarantee. OPTM's published work covers biomarker diagnostics, pain protocols, and phytotherapeutic approaches, while individual results depend on the condition, grade, medical history, and whether surgery is clinically necessary.

What journals have published OPTM's research?

Dr. Apurba Ganguly's work is linked from this page across PubMed Central, IOMC Proceedings, IABCR, Longdom Publishing, JDDT, and other journals. Links open the source publication or author profile so readers can inspect the study rather than relying on a marketing summary.

What do the clinic outcome numbers mean?

The clearest documented figure is the 89% knee-replacement avoidance rate in a 1,000+ patient Grade 1-3 knee cohort observed from 2019 to 2024. It applies to that defined cohort and should not be presented as a success rate for every condition or every patient.

Awards & International Recognition

Awards are not the protocol. They are what other bodies said after looking at the work.

Rose of Paracelsus Award

European Medical Association (EMA)

2022

For work in natural medicine and clinic pain-care protocols

National Recognition

Ministry of AYUSH, Government of India

2023

Recognition connected with the founder's phytomedicine and pain-research work

If the papers match what you have, book the bloodwork

100,000+ patients have already gone through this protocol. The next visit is an assessment, not a surgery date.

Learn About Our Process